Breaking News

Baxter, Oasmia Ink Apealea Commercial Mfg. Pact

Apealea will be manufactured at Baxter’s cytotoxic manufacturing site in Germany

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Oasmia Pharmaceutical AB signed a new five-year contract with Baxter BioPharma Solutions for global commercial manufacturing of Apealea. Technology transfer to Baxter is complete and manufacturing is planned to commence soon. Terms of the agreement were not disclosed. Apealea will be manufactured at Baxter’s manufacturing site in Halle/Westfalen, Germany, a facility for cytotoxic contract manufacturing. Oasmia plans to shift its manufacturing at its site in Uppsala to focus on its other produ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters